Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2234-2244

  Lønning, Per Eystein ^a   Bajetta, Emilio ^a   Murray, Robin ^a   Tubiana Hulin, Michèle ^a   Eisenberg, Peter D ^a   Mickiewicz, Elizabeth ^a   Celio, Luigi ^a   Pitt, Paula ^a   Mita, Monica ^a   Aaronson, Neil K ^a   Fowst, Camilla ^a   Arkhipov, Alexei ^a   Salle, Enrico Di ^a   Polli, Anna ^a   Massimini, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN BLOOD LEVEL; FATIGUE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 17144472154     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2234     Document Type: Article

References (30)

1. Hortobagyi GN: Drug therapy: treatment of metastatic breast cancer. N Engl J Med 339:974-984, 1998
2. Kimmick GG, Muss HB: Endocrine therapy in metastatic breast cancer. Cancer Treat Res 94:231-254, 1998
3. Osborne CK: Drug therapy: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
4. Taylor SG 4th, Gelman RS, Falkson G, et al: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455-461, 1986
5. Di Salle E, Ornati G, Giudici D, et al: Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43:137-143, 1992
6. Lønning PE, Dowsett M, Powles TJ: Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35:355-366, 1990
7. Brodie AM, Garrett WM, Hendrickson JR, et al: Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38:693-702, 1981
8. Miller WR: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16:83-93, 1989
9. Murray R, Pitt P: Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35:249-253, 1995
10. Geisler J, Johannessen DC, Anker G, et al: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer 32A:789-792, 1996
11. Lønning PE: Pharmacology of new aromatase inhibitors. Breast 5:202-206, 1996
12. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998
13. Johannessen DC, Engan T, Di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997
14. Poggesi I, Jannuzzo MG, Di Salle E, et al: Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynamics (PD) of a single oral dose of exemestane (Aromasin, EXE). Proc Am Soc Clin Oncol 18:193a, 1999 (abstr 741)
15. Purohit OP, Anthony C, Radstone CR, et al: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558, 1994
16. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
17. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996
18. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
19. Brun B, Benchalal M, Lebas C, et al: Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors. Cancer 79:2137-2146, 1997
20. Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 16:3720-3730, 1998
21. Porkka K, Blomqvist C, Rissanen P, et al: Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12:1639-1647, 1994
22. Garcia-Giralt E, Ayme Y, Carton M, et al: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24:139-145, 1993
23. Ingle JN, Johnson PA, Suman VJ, et al: A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 80:218-224, 1997
24. Thürlimann B, Paridaens R, Serin D, et al: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II, multicentre multinational study. Eur J Cancer 33:1767-1773, 1997
25. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials - Arimidex Study Group. Cancer 83:1142-1152, 1998
26. MacNeill FA, Jones AL, Jacobs S, et al: The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66:692-697, 1992
27. Geisler J, Lundgren S, Berntsen H, et al: Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:2687-2693, 1998
28. Geisler J, King N, Dowsett M, et al: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74:1286-1291, 1996
29. Dowsett M, Jones A, Johnston SRD, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995
30. Di Salle E, Ornati G, Paridaens R, et al: Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304), in Motta M, Serio M (eds): Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, the Netherlands, Elsevier Science BV, 1994, pp 303-310